Bacterial Infections

Prosthetic joint infections (PJI) are difficult to treat and require a multidisciplinary approach including surgical and therapeutic approaches to overcome infection. We were delighted to speak with Dr. Robin Patel (Mayo Clinic, Rochester, MN, USA) to learn more around the incidence, pathogenesis, and prognosis of PJI, the challenges in diagnosis and treatment of PJI and […]

Clostridioides difficile infection (CDI) is usually associated with older age; however, is becoming more prevalent in paediatric patients often in concurrence with comorbidities. There remains many unmet needs in the diagnosis and treatment of CDI in paediatric patients, with the mainstay of treatment being antibiotics. touchINFECTIOUS DISEASES spoke with Dr. Anne J. Gonzales-Luna (University of […]

Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use […]

Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is one of the more severe forms of MRSA. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss the use of linezolid as a treatment option for MRSA bacteraemia infection. Dr Stover Hielscher discusses drug interactions, […]

In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals and antibiotics. Interviews available in this series: Respiratory syncytial virus (RSV) – Health burden […]

Multidrug-resistant tuberculosis (MDR-TB) refers to the case when a clinical TB isolate is resistant to two of the most potent tuberculosis medications: isoniazid and rifampin. Globally, there are about half a million new cases of MDR-TB per year. Prof. Timothy Rodwell (UC San Diego, San Diego, CA, US) talked to us about the advantages, efficacy and cost-effectiveness […]